Price
No data yet.
Social Signal Score
Revenue
$490.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Evans
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 540
- Beta
- 2.21
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.74
Financials
Revenue
$490.0K+8066.7%Net Income
$-122.68MEBITDA
$-125.02MFree Cash Flow
$-68.51MEPS (diluted)
$-1.18Shares Outstanding (diluted)
104.33M+8110.0%Operating Expenses
$127.04MCash & Debt
$1.15BDividend per Share
$0.23Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $139.74M | $-79.99M | $-0.81 |
| 2024 | $63.52M | $-376.74M | $-4.58 |
| 2023 | $377.71M | $-132.53M | $-1.72 |
| 2022 | $60.92M | $-289.09M | $-4.13 |
| 2021 | $51.84M | $-370.64M | $-5.77 |
| 2020 | $24.0K | $-194.59M | $-5.49 |
| 2019 | $18.0K | $-78.33M | $-1.53 |
| 2018 | $0.00 | $-115.26M | $-3.28 |
| 2017 | $0.00 | $-8.73M | $-0.62 |
Valuation
BEAMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newszacks.com·5h ago·Positive
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $-1.16 per share
Typical surprise -4.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.18 vs $-1.11miss
- Thu, May 7$-0.91 vs $-0.87miss
- Tue, Feb 24$-0.10 vs $-1.13beat
- Tue, Nov 4$-1.10 vs $-0.98miss
- Tue, Aug 5$-1.00 vs $-1.04beat
- Tue, May 6$-1.24 vs $-1.11miss
Estimates and results for BEAM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BEAM officers and directors.
- Bought
- —
- Sold
- $22.2m
0 trades
42 trades
- Simon Amysold
- Simon Amysold
- Evans John M.sold
- Evans John M.sold
- Evans John M.sold
- Evans John M.sold
- Fmr Llcsold
- Fmr Llcsold
58 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.